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1. To understand the real world from
which their patients were selected,
we need to know how many patients
were refused entry into their study.
2. The benefits of combined resection
and radiation therapy might be put
into better perspective if we could
see the survival data and curves on
the patients refused entry into the
study. All hospital tumor boards cer-
tified by the American Cancer Soci-
ety will have this information.
3. Because early studies by Devalle
and coworkers2 indicated a late sur-
gical mortality of 11% beyond the
usual 30-day perioperative period, it
is important to learn whether such
events still occurred in the 1990s.
Similarly, early reports noted by
Ruffie and colleagues3 indicated
10% late suicides after surgery. A
statement regarding the occurrence
or nonoccurrence of suicidal deaths
during long-term follow-up is im-
portant in assessing the quality of
life and the suffering of the patients.
4. What were the lengths of the hospi-
tal stays of the included and the ex-
cluded surgical groups? How many
days of hospitalization were required
in long-term follow-up for the com-
plications of radiation therapy and
surgery? These data are important in
assessing the patients’ quality of life
as well as the cost of care.
5. How many of the patients had large
recurrent or persistent pleural effu-
sions? Several investigators have
suggested a survival advantage for
this group relative to those with a
soft-tissue mass.
6. It is interesting that 69% of this se-
lected group of surgical patients had
such high staging (III and IV). By
comparison, Sugarbaker and associ-
ates4 found 136 of 183 (74%) to
have stage I and II disease in a series
that had excluded 2 to 3 patients for
every patient accepted. Does this dif-
ference indicate that Sugarbaker and
associates4 had a more effective
technique to screen out patients with
stage III and IV disease for surgical
resection? It is disappointing that so
few patients with stage I and II dis-
ease were found in the study of
Rusch and colleagues.1 Perhaps rig-
orous intraoperative staging up-
grades preoperative stage to the ex-
tent that few patients with stage I
and II disease remain, even with
prompt evaluation after the onset of
symptoms. Presumably nonsurgical
disease would be falsely staged
lower because of the absence of me-
diastinal sampling, laparoscopy, and
so on, making comparison of surgi-
cal and nonsurgical groups more dif-
ficult.
7. The median survival was stated to be
17 months in this study, but that
number excluded the 7 deaths and
the 21 patients whose disease could
not be completely resected. Obvi-
ously, we need to know the median
survival of all patients operated on,
including perioperative deaths, if we
are to provide honest informed con-
sent with surgical referrals.
8. Rigorous statistical assessment of
surgical trials becomes even more
important in light of a recent consec-
utive, unselected series of 26 pa-
tients with malignant mesothelioma
with pleural effusion and treated by
medical thoracoscopic talc pleurode-
sis as the primary modality of care.
They had a median survival of 19.4
months and have a mean survival
that is now reaching 22.8 months.5-7
Although Rusch7 has previously in-
dicated the difficulties of doing ran-
domized controlled studies in this
disease, such studies may be neces-
sary to separate theoretic from the
real benefits of surgery.
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Early bypass occlusion in patients
with the St Jude Medical Symmetry
connector
To the Editor:
In recent years, off-pump coronary artery
bypass grafting has gained increasing ac-
ceptance because of the reduction of pos-
sible negative effects of extracorporeal cir-
culation. This technique was shown to be
beneficial, especially in elderly patients.1
However, the manipulation of a possibly
diseased ascending aorta in elderly patients
might increase the risk for neurologic com-
plications.2
In May 2000, St Jude Medical, Inc
(Minneapolis, Minn) introduced an anasto-
motic device (Symmetry Aortic Connector
System) to facilitate the proximal vein–
aorta anastomosis without side clamping
the aorta. Since June 2001, we have used
the Symmetry mechanical anastomotic de-
vice preferably in off-pump coronary artery
bypass grafting procedures, especially
when transesophageal echocardiography
revealed a calcified ascending aorta.3 Be-
tween June 2001 and April 2002, we have
deployed the device in 51 male and 10
female patients (mean age, 68.6  8.6
years). A total of 77 Symmetry connectors
were used (1.3 per patient). Loading of the
connector was simple, and time for anasto-
mosis was less than 15 seconds. After de-
ployment, the free graft flow was assessed
by removing the bulldog clamp from the
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vein before the distal anastomoses were
performed. In case of uncertainty or bleed-
ing, the Symmetry connector was replaced.
Before closing the chest, we reassessed
flow with an additional measurement by
using the transit time flow probe (Medi-
Stim, Oslo, Norway).
No neurologic deficiencies were ob-
served, and 54 of 61 patients had an un-
eventful postoperative course. However, in
7 (11.5%) of 61 patients, we encountered
device-related complications: in 1 patient
occurring intraoperatively, in 2 patients
within 5 days after the operation, and in 4
patients within 6 months postoperatively.
Six patients were subjected to repeat
coronary angiography: 1 patient had ven-
tricular fibrillation and consequent resusci-
tation; 5 patients had a recurrence of an-
gina, dyspnea, or both; and 1 patient had
loss of flow detected intraoperatively with
a new image system (Spy Novadaq, To-
ronto, Ontario, Canada). This occlusion
was due to an aortic plaque that was not
properly cut by the Symmetry cutter and
therefore closed the new aortic opening
like a cover. Repeat angiography in 6 of 7
patients showed an occlusion of the vein
graft right at the neo-ostium. Kinking of
the graft was never observed as a possible
cause of closure. Three patients underwent
reoperation within 6 days. In 1 patient the
graft was dilated, in 2 patients the graft was
stented, and in 1 patient further treatment
was not considered necessary because of
the small size of anastomosed artery.
On the basis of these observations, we
have stopped the routine use of the Sym-
metry connector and reserve the device for
patients who have a severely calcified as-
cending aorta (grade IV-V), in whom other
alternative techniques (vein anastomosis to
the internal thoracic artery or to the innom-
inate artery) are not possible.
Although we fully acknowledge the po-
tential benefits of a nontouch vein graft–
aorta anastomosis, further investigations
and possibly improvements of the connec-
tor are necessary to evaluate the potential
benefits of this interesting technology.
Oliver Reuthebuch, MD
Mario Lachat, MD
Alexander Kadner, MD
Marko Turina, MD
Clinic for Cardio-vascular Surgery
University Hospital Zurich
Ramistrasse 100
CH-8091 Zurich, Switzerland
References
1. Al-Ruzzeh S, George S, Yacoub M, Amrani
M. The clinical outcome of off-pump coro-
nary artery bypass surgery in the elderly
patients. Eur J Cardiothorac Surg. 2001;20:
1152-6.
2. Yokoyama T, Baumgartner FJ, Gheissari A,
Capouya ER, Panagiotides GP, Declusin
RJ. Off-pump versus on-pump coronary by-
pass in high-risk subgroups. Ann Thorac
Surg. 2000;70:1546-50.
3. Ribakove GH, Katz ES, Galloway AC,
Grossi EA, Esposito RA, Baumann FG, et
al. Surgical implications of transesophageal
echocardiography to grade the atheroma-
tous aortic arch. Ann Thorac Surg. 1992;53:
758-63.
doi:10.1067/mtc.2003.250
Horner syndrome
To the Editor:
I compliment Naimer and associates1 for
drawing attention to the important problem
of Horner syndrome after manipulation of
the subclavian artery in the neonate. As
Naimer and associates1 pointed out in their
report, there are remarkably few references
to this complication. Although Horner syn-
drome may seem to be a minor problem to
physicians caring for children with com-
plex congenital heart disease, its cosmetic
consequences are certainly not viewed
lightly by parents of affected children.
Horner syndrome not only has been de-
scribed after subclavian flap aortoplasty, as
in the report by Naimer and associates,1 but
also is seen regularly after a thoracotomy
approach to construction of either a modi-
fied or classic Blalock shunt. I believe that
this is one of the important advantages of
approaching construction of a modified
Blalock shunt through a median sternot-
omy. In our 1995 report,2 my colleagues
and I found no cases of Horner syndrome
among 52 patients who had a modified
Blalock shunt constructed through a ster-
notomy approach. We also found a signif-
icantly lower probability of shunt failure
with the sternotomy approach than with the
thoracotomy approach. I believe that the
sternotomy approach is technically easier
and less likely to result in distortion of the
hilar branches because the distal anastomo-
sis is placed more proximally on the branch
pulmonary artery. This also facilitates sub-
sequent takedown of the shunt. In contrast
to our experience with the sternotomy ap-
proach, we found that 2 of 16 patients who
underwent a thoracotomy approach as part
of first-stage preparation for a rapid two-
stage arterial switch had Horner syndrome
develop.2
I am in complete agreement with the
conclusion of Naimer and associates1 that
there are probably many unidentified cases
of Horner syndrome that occur after ma-
nipulation of the neonatal subclavian ar-
tery. Careful consideration should be given
to choosing surgical techniques and ap-
proaches that avoid manipulation of the
subclavian artery in the region of the sym-
pathetic pathway.
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Impact of comorbidity on survival
after surgical resection in patients
with stage I non–small cell lung
cancer
To the Editor:
I read with interest the recent article by
Battafarano and associates1 on significantly
adverse impact of comorbidity on survival
of patients with resected stage I non–small
cell lung cancer. Although the vast major-
ity of patients with early stage (I and II)
disease are treated with surgery, a small
subset of these patients are not candidates
for surgery because of preexisting comor-
bidity. Such patients are treated with radio-
therapy alone.2-9 In this patient population
high-dose, standard fraction, or hyperfrac-
tionated radiotherapy is capable of achiev-
ing median survivals as long as 30 months
and 5-year survivals as great as 30%,7,8
with values going up to approximately 40
months and 40%, respectively, for T1 N0
cases.9
This patient population clearly repre-
sents a case of extremely negative selec-
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